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Abstract 
CRISPR/Cas has the potential to revolutionize medicine, agriculture, and the way we understand life 
itself. Understanding the trajectory of innovation, how it is influenced and who pays for it, is essential 
for such a transformative technology. The University of California and the Broad/Harvard/MIT systems 
are the two most prominent academic institutions involved in the research and development of 
CRISPR/Cas. Here we present a model of co-funding networks for CRISPR/Cas research at these 
institutions, using funding acknowledgments to build connections. We map papers representing 95% 
of citations on CRISPR/Cas from these institutions grouped by the stage each represents in the 
research translation process (as a biological phenomenon, as a research tool, as a set of technologies, 
and applications of that technology), and use a novel technique to analyse the relationships between 
the structures of the co-funding networks, the phase of research, and funding sources. The co-
funding subnetworks were similar in that US government research funding played the decisive role in 
early stage research. Research at Broad/Harvard/MIT is also strongly supported by 
philanthropic/charitable organizations in later stages of the translation process, clustered around 
certain topics. Applications for CRISPR technologies were underrepresented, which bolsters findings 
on the preponderance of the US private sector in developing applications, and the disproportionate 
number of Chinese institutions filing patents for industrial and food systems applications. These 
network models raise fundamental questions about the role of the state in supporting breakthrough 
innovations, risk, reward, and the influence of the private sector and philanthropy over the trajectory 
of transformative technologies. 
 
Introduction 
CRISPR/Cas are a set of versatile technologies aimed to manipulate, analyse and visualize the 
biomolecular machinery of living organisms. [1] CRISPR has the potential to revolutionize medicine, 
[2-4] agriculture [5] and the way we understand life itself. [6] Applications for these technologies have 
been proposed in fields as diverse as pharmaceuticals, [7] crop breeding, [8] livestock, [9] industrial 
biotechnology [10] and pest control. [11] As one of the most potentially transformative technological 
breakthroughs of the last decade, it is important to understand CRISPR/Cas innovation trajectories, 
who finances them, who bears the risks and rewards of innovation and for who technologies are 
ultimately developed. CRISPR/Cas been analysed by a myriad of historical, legal, ethical, policy and 
scientometrics approaches. The social and humanities discussion on CRIPSR/Cas technologies ranges 
from ethical concerns about heritable genome editing [12] to intellectual property [13, 14] and 
democratization and governance of these technologies [15].  Despite the diversity of social sciences 
and humanities studies on these technologies there is a lack of knowledge on the role of the different 
types of financing of CRISPR/Cas research.  
Since the Second World War in the period known as the golden age of capitalism, government 
agencies have been the main source of funding for scientific research. [16] Breakthrough technologies 
have emerged from long term public good missions, with government agencies actively shaping 
markets and taking on the risk of early stage transformative research investments, while private 
sector roles have traditionally been limited to lower risk forms of integration of technologies, 
development and marketing later in the innovation process. [17] Early research progress on genome 
technologies (Viral vectors, RNAi, and the different genome editing platform) largely followed this 
pattern, with the US National Institutes of Health playing a leading role in funding innovation over the 
past 30 years. [18] Scientometrics studies on the impact of US government institutions like the 
National Science Foundation and the National Institutes of Health show that these institutions still 
function as global driving forces of innovation writ large [19, 20]. However, there has been a clear 
decline in US government support to science in recent years when measured as a percentage of gross 
domestic product, [21] while simultaneously a second golden age in the economic power of 
philanthropic and charitable organizations is taking place in the United States. [22] The emerging 
active role of philanthropic foundations as patrons of science has serious implications for the 
governance of science and technology. For example, Anne-Emanuelle Birn has documented the 
capacity of philanthropy to change the global research agenda on health from a focus on the social 
determinants of health to sophisticated technological solutions, with mixed results. [23] Similarly, the 
participation of philanthropic organizations in the area of agriculture and food sciences is currently 
promoting the development and implementation of “silver bullet” technologies that allow the 
incorporation of farmers into the commercial value chains. [24] Moreover, an investigation on the 
role of science philanthropy in US research universities showed how this type of organization 
concentrates their efforts in the translation of knowledge from basic research to the development of 
applications, much like other private sector actors. [25] Understanding the different types of funding 
to the different levels of research from basic science to the development of technologies to their 
application in specific industries can provide us fundamental information on the influence of these 
different organizational actors on the development and implementation of CRISPR/Cas technologies. 
The University of California System and the Broad/Harvard/MIT systems are the two most prominent 
academic institutions involved in the research and development of CRISPR/Cas technologies. The 
impact of these two research systems on the invention and development of CRISPR/Cas technologies 
has been well documented. [14, 18, 26] Therefore, these institutions are an excellent case study to 
examine the evolution of these technologies, the funding networks that support them, and the 
relationships between innovation, financing, production and property rights over these technologies. 
In the present investigation we aim to map and critically analyse the organization of the co-funding 
networks of the research on the CRISPR/Cas technologies performed at the UC and the 
Broad/Harvard/MIT systems. Doing so raises fundamental questions about the role of the state in 
supporting breakthrough innovations, risk, reward, and democratic influence over the trajectory of 
transformative technologies.  
Methodology 
1. A search of peer-reviewed papers was performed in the Web of Science [27] on May 25, 
2020. The research criteria are listed in table 1. A very similar number of papers was found for 
the UC system and the Broad/Harvard/MIT system (920 and 922 respectively, See table 1). 
For each system we selected a number of top cited papers that concentrated approximately 
95 percent of the citations received.  That is, we wanted to focus our explorative analysis in 
the most influential papers from each institutional system. Around the top 40% of top cited 
papers accumulated 95% of citations while the remaining 60% of the papers received just 5% 
of citations (Table 1).   
 
 
Table 1. Search criteria, number of papers found in the Web of Science (WoS), number of papers 
selected and number of papers forming the co-funding network models. 
Broad/Harvard/MIT system 
Search criteria: 
ORGANIZATION-ENHANCED: (Broad Institute or Massachusetts Institute of Technology (MIT) or Harvard 
University) AND TOPIC: (Cpf1 or Cas12a or CRISPR or "clustered regularly interspaced short palindromic 
repeats" or Cas9). Refined by: DOCUMENT TYPES: (ARTICLE) 
Total of papers found in the WoS (by April 25, 2020) 922 
Total of papers selected from WoS with at least 25 citations (Receiving 95.2% of citations) 364 
Unrelated papers identified during the classification process 3 
Papers with no reporting funding 8 
Papers in the network model 355 
University of California System 
Search criteria: 
ORGANIZATION-ENHANCED: (University of California System) AND TOPIC: (Cpf1 or Cas12a or CRISPR or 
"clustered regularly interspaced short palindromic repeats" or Cas9). Refined by: DOCUMENT TYPES: 
(ARTICLE) 
Total of papers found in the WoS (by April 25, 2020) 920 
Total of papers selected from WoS with at least 15 citations (Receiving 94.8% of citations) 400 
Unrelated papers identified during the classification process 16 
Papers with no reporting funding 9 
Papers in the network model 375 
 
2. A bimodal network model of papers and co-funding organizations was built for each 
institutional system by using the information reported in the acknowledgment section of the 
papers. It is important to mention that some of the selected papers did not report any source 
of funding while other papers were unrelated to CRISPR/Cas as a research topic and therefore 
were not included in the co-funding network models (Table 1). 
3. The papers in the bimodal network models were classified in different levels of research as 
follows: A) Papers reporting/mentioning CRISPR/Cas as a part of a biological phenomenon. 
That is, papers investigating CRISPR/Cas as bacterial immune systems; the interactions of 
their component in bacteria or archaea, and/or the molecular, ecological or evolutionary 
interactions of these systems with the bacteriophage viruses. B) Papers reporting the use of 
CRISPR/Cas as a research tool. In these papers CRISPR/Cas is not the central object of 
investigation but an instrument to identify or analyse the role of specific genes in normal or 
pathological biological processes. C) Developments or improvements of CRISPR/Cas 
technologies. That is, these papers report discoveries of alternative CRISPR genome editing 
systems which could be more efficient, more versatile or easier to use; investigations aimed 
to overcome the technical difficulties to apply the technology in different organisms; or 
investigations reporting molecular mechanisms that can be used to modulate the activity of 
Cas enzymes. D) Papers reporting applications of CRISPR/Cas in biomedicine, food systems, 
environmental systems, or industrial biotechnology. E) Social studies of science papers. For 
example papers reporting the ethical or societal implications of CRISPR technologies. 
4. A correspondence analysis of the content of the papers was performed by using the software 
KH Coder [28] In order to determinate if papers previously classified in the same type of 
research tend to have a similar distribution of terms. 
5. The co-funding organizations in the bimodal network models were classified as follow: A) 
United States government agencies. Any public source of funding in the USA including federal, 
state and local agencies except those belonging to the United States Armed Forces. B) 
Institutions belonging to the United States Armed Forces. Even though these institutions are 
US government agencies, they follow a distinctive logic in which the research efforts are 
either aimed to increase the strategic technological advantage over rivals and enemies [29] or 
to satisfy the particular needs of the armed forces like the health needs of the military 
personnel. [30] C) Philanthropic or charitable organizations. That is, non-profit organizations 
that are tax-exempt under 501(c)(3) requirements in the USA. [31] D) For-profit organizations. 
That is, organizations aimed to earn profit through activities and that are concerned with 
their own economic interests. E) Academic institutions, professional organizations or medical 
research centres. Funding sources from countries other than the USA are classified in 
equivalent categories: governmental or intergovernmental agencies, philanthropic or 
charitable organizations, for-profit organizations and academic organizations. 
6. The co-funding network models were visualized and analysed with Cytoscape. [32] 
Subnetworks of specific levels of research and/or types of sources of research funding were 
built and compared in terms of their density or number of sources per paper.  
Results 
The network models 
A co-funding network model was built for each institutional system. The bimodal network model of 
the Broad/Harvard/MIT system was formed by 738 funding sources, 355 papers and 2,267 funding 
acknowledgements (Fig. 1) while the bimodal network model of the UC system was formed by 714 
funding sources, 375 papers and 1,750 funding acknowledgements (Fig 2). The funding 
acknowledgements are the links that connect the funding sources to the papers. Therefore, they are 
the more relevant elements in the network model in order to understand the structural differences 
between the funding of the CRISPR/Cas research in the studied institutional systems and the different 
research levels. In that sense, a first observation is that even though the numbers of papers and 
funding sources are similar, these two network models exhibit clear differences in terms of density as 
there are just an average of 4.7 funding acknowledgements per paper in the case of the UC system 
while the Broad/Harvard/MIT system has 6.4 funding acknowledgements per paper. 
 
Figure 1. The co-funding network model of top cited CRISPR/Cas research in the Broad/Harvard/MIT 
system. This is a bimodal network model made of papers and funding sources. “Filled” nodes are 
institutions while "empty” nodes are papers. The colour and shape of the nodes indicates the type of 
organization these nodes represent as it is shown in the figure legend. The grey links connecting 
papers with the funding sources represent the funding acknowledgements. 
  
 
 
Figure 2. The co-funding network of top cited CRISPR /Cas research in the UC system. This is a bimodal 
network model made of papers and funding sources. “Filled” nodes are institutions while "empty” 
nodes are papers. The colour and shape of the nodes indicates the type of organization these nodes 
represent as it is shown in the figure legend. The grey links connecting papers with the funding 
sources represent the funding acknowledgements. 
Papers in the network model by research level and type of funding source 
The results of the classification of papers in the network models are summarized in table 2. Around 
half of the papers in the network models of both institutional systems were reporting the use of 
CRISPR/Cas as a research tool (Table 2). However, there are differences between both intuitions as 
the UC system tend to be comparatively more oriented towards basic biological research than the 
Broad/Harvard/MIT system while the latter focuses more in the development of improved CRISPR/Cas 
technologies (Table 2). 
Table 2. Number of papers in the network models by type of research 
 
Broad/Harvard/MIT system 
Biological phenomenon 14 (3.9%) 
Research tool 206 (58%) 
Developments or improvements of the technology 105 (29.6%) 
Applications of the technology 29 (8.2%) 
Social studies of science 1 (0.3%) 
Total of papers in the network model 355 (100%) 
  
University of California System 
Biological phenomenon 68 (18.1%) 
Research tool 189 (50%) 
Developments or improvements of the technology 69 (18.4%) 
Applications of the technology 48 (12.8%) 
Social studies of science 1 (0.3%) 
Total of papers in the network model 375 (100%) 
 
A complementary strategy to gather evidence on the accuracy of the classification -which was human-
made in base to the criteria mentioned in the methodology- was to perform a correspondence 
analysis of the content of the papers so that we could see if papers of the same type of research tend 
stick together in the plot. That is, we wanted to know if a statistical analysis of the distribution of 
terms among the papers performed by the application KH Coder [28] could distinguish between the 
different types of research in a comparable as the human-made classification. The resulting plot 
suggests that the correspondence analysis of the content of the papers distinguished well between 
the three most numerous types of investigations: papers reporting developments or improvements of 
the technology, the use of CRISPR/Cas as a research tool and the study of CRISPR/Cas as a biological 
phenomenon (S1 Fig). However, the papers related to the different areas of application were 
dispersed around the plot probably due to their smaller number and the diversity of their content (S1 
Fig). On the other hand, the correspondence analysis plot displaying the papers grouped by type of 
investigation and institution suggest that papers from the same research level but from different 
institutional systems have a similar content (S2 Fig). 
There are not observable differences between the UC system and the Broad/Harvard/MIT system in 
terms of the number of papers supported by the different types of funding sources (Table 3). For both 
systems around half of the papers reported financial support from entities outside the United States 
while around 90 percent of the papers were funded by US institutions. For both systems the US 
governmental agencies were by far the main type of funding source followed by US academic entities 
(Which include universities, research medical centers and professional organizations) and in third 
place US philanthropic or charitable organizations (Table 3). 
Table 3. Number of papers for type of funding sources in the co-funding network models. It is 
important to mention that these numbers overlap, as one paper can be funded by several 
organizations. 
Broad/Harvard/MIT system   
International funding sources 179 (50.4%) 
International philanthropic or charitable 64 (18%) 
International governmental or intergovernmental 133 (37.5%) 
International academic entities 53 (14.9%) 
International for-profit 14 (3.9%) 
USA funding sources 341 (96%) 
US governmental agencies 318 (89.6%) 
US academic entities 203 (57.2%) 
US philanthropic or charitable organizations 189 (53.2%) 
US for-profit 16 (4.5%) 
US armed forces 62 (17.5%) 
Total of papers in the network model 355 (100%) 
  
University of California System   
International funding sources 165 (44%) 
International philanthropic or charitable 53 (15.2%) 
International governmental or intergovernmental 124 (33%) 
International academic entities 51 (13.6%) 
International for-profit 15 (4%) 
USA funding sources 343 (91.5%) 
US governmental agencies 318 (84.8%) 
US academic entities 190 (50.7%) 
US philanthropic or charitable organizations 157 (41.8%) 
US for-profit 23 (6.3%) 
US armed forces 34 (9.1%) 
Papers in the network model 375 (100%) 
 
Table 4 lists the main funding sources of CRISPR research for each institutional system. The top four 
reported funding sources (The US National Institutes of Health, the National Science Foundation, the 
Howard Hughes Medical Institutes and the NIH National Cancer Institute) are the same for both 
institutions and they are ranked in the same order.  There are two philanthropic (The Simons and the 
Vallee Foundations) and one charitable organization (The New York Stem Cell Foundation) among the 
top ten funding sources for CRISPR/Cas research at the Broad/Harvard/MIT system while only one 
charitable organization is among the top ten financers of the CRISPR/Cas research at the UC system. 
Interestingly, the financing of CRISPR/Cas research at the UC system seems to be much more 
centralized than in the case of the Broad/Harvard/MIT system as the number of papers per source 
financed drop more sharply than in the case of the UC system as the rank progresses (Table 4). 
Table 4. Top ten research funding sources for CRISPR/Cas research at the University of California and 
Broad/Harvard/MIT systems. 
University of California System Broad/Harvard/MIT sytem 
Main funding sources Number of 
funded papers 
in giant 
component 
Main funding sources Number of funded 
papers in giant 
component 
National Institutes of Health 
NIH 
250 National Institutes of Health NIH 291 
  
National science foundation 
NSF 
97 National science foundation NSF 62 
Howard Hughes Medical 
Institute 
65 Howard Hughes Medical Institute 60 
  
National Cancer Institute NCI 28 National Cancer Institute NCI 45 
National Institute of General 
Medical Sciences NIGMS 
28 US Department of Defence 43 
California Institute for 
Regenerative Medicine  
27 Simons Foundation 41 
Burroughs Wellcome Fund 20 Vallee Foundation 39 
US Department of Energy DOE 17 New York Stem Cell Foundation 36 
  
National Natural Science 
Foundation of China 
15 National Institute of Mental Health 
NIMH 
35 
US Department of Defence 14 National Institute of General Medical 
Sciences NIGMS 
32 
National Human Genome Research 
Institute NHGRI 
32 
Structural difference between subnetworks corresponding to different funding sources and research 
levels 
Figures 3 and 4 show the subnetworks generated corresponding to the different research levels and 
types of funding sources, and the intersections between these. It is important to keep in mind that a 
rate near to 1 funding acknowledgement per paper is related to very sparse co-funding subnetworks 
whiles a rate near to 2 or above means that the co-funding subnetwork is dense. As a matter of fact, a 
rate of 1 means that there is no co-funding at all. The co-funding subnetworks showed structural 
differences between the different types of funding sources and research levels in terms of density, 
i.e., funding acknowledgement per paper (Fig 3 and 4). The co-funding subnetworks showed a similar 
intensity of support from the US governmental agencies to the CRISPR research in both institutional 
systems but only the research at the Broad/Harvard/MIT system is strongly supported by 
philanthropic/charitable organizations and by international sources and foreign governmental 
agencies (Fig 3 and 4). Moreover, differences in the financing of specific types of funding to specific 
types of research were identified. Particularly, a dense network of philanthropic/charitable 
organizations can be observed supporting research on the technical improvement of the CRISPR/Cas 
technologies at Broad/Harvard/MIT while a sparser and smaller network of philanthropic/charitable 
organizations supports the same type of research at the UC system (Fig 3 and 4). Figure 3 shows a 
dense subnetwork of governmental agencies supported the different stages of the CRISPR/Cas 
research performed at the UC system: from the study of CRISPR systems as biological phenomena to 
its use as a research tool, the continuous development of CRISPR technologies, and the application of 
CRISPR as a component of biomedical therapies. However, the participation of the other types of 
funding sources was minimal except the punctual co-funding efforts of charitable/philanthropic 
organizations and foreigner governmental agencies subnetworks to some specific research levels (Fig 
3). In the case of the Broad/Harvard/MIT system, the models illustrate consistent support of 
subnetworks of US governmental agencies, foreign organizations and charitable/philanthropic 
organizations to the different levels of research from the most basic research types to the 
development, improvement and application of CRISPR/Cas technologies (Fig 4). It is interesting to 
notice that the US armed forces, philanthropic organizations and international governmental agencies 
have a concentrated participation in the co-funding of the technical improvement of CRISPR/Cas 
technologies (Fig 4). Overall, both systems are strongly supported by a diversity of funding sources 
(Fig 3 and 4).  
 
 Figure 3. Subnetworks, number of papers (N) and grant acknowledgements per paper (A/N) by type of 
funding source and research levels in the co-funding network model of CRISPR/Cas research at the 
University of California System. The numbers can overlap as one paper can be funded by two or more 
types of agencies.  
 Figure 4. Subnetworks, number of papers (N) and grant acknowledgements per paper (A/N) by type of 
funding source and research levels in the co-funding network model of CRISPR/Cas research at the 
Broad/Harvard/MIT system. The numbers can overlap as one paper can be funded by two or more 
types of agencies.   
Discussion 
The use of the funding acknowledgment sections as a source of data for scientometrics studies has 
been extensively discussed in the recent years. [27, 33-36] However, despite the enormous potential 
of using this source of data to investigate the impact of the funding entities on the development of 
science and technology there are some important considerations that must be taken into account. 
Firstly, it is important to consider that our investigation was based in the information provided by the 
Web of Science (WOS) which began systematically collecting acknowledgments information in 2008 
[33] becoming the de facto standard source of information for this type of investigation. In that sense, 
a comparative analysis of the three main bibliometric databases (WOS, PubMed and Scopus) found 
that the WOS outperforms the other databases in terms of the proportion of articles in with funding 
information. [34] Secondly, social sciences, humanities and non-English language journals are 
underrepresented in both WOS and Scopus. [27] In the case of the WOS, specifically, the Arts & 
Humanities Citation Index (AHCI) content is not indexed for funding acknowledgement data and there 
are problems covering this information for non-English language papers. [35] Third, a loss of funding 
information of 12% has been reported for the WOS. [36] Finally, the main challenge regarding the use 
of this source is that authors do not adequately report their sources of funding, misspell funding 
bodies, or put erroneous grant numbers. [35, 36]  In the present investigation, despite the fact that 
the Web of Science has systematized financing data, the name of each reported organization was 
carefully reviewed and errors were corrected. Previous studies reporting the use of funding 
acknowledgment sections focused on analysing the impact of specific funding sources by using 
traditional metrics such as the number of citations per paper. As far as we know, this is the first time 
that the funding acknowledgment is used to build and analyse the relationships between the 
structures of the co-funding networks, the research level and the type of sources.  
Our results suggest that even though US government agencies extensively supported all the levels of 
CRISPR/Cas research in both institutional systems, subnetworks of US military agencies, philanthropic 
organizations and international governmental agencies have concentrated participation in co-funding 
the technical improvement of CRISPR/Cas technologies in the case of the Broad/Harvard/MIT system. 
This is consistent with our previous investigation on the global organization of CRISPR/Cas research 
which showed that both the University of California and the Broad/Harvard/MIT system have a 
leading role in the different stage of the CRISPR/Cas research, supported predominantly by US 
government agencies. [18] Interestingly, in the same investigation we identified a cluster of papers, 
i.e., a dense region in the citation networks, related to the discovery and development of genome 
editing platforms analogous to the CRISPR/Cas9 system. [18] The leading research in this cluster was 
supported by a set of philanthropic organizations. [18] Together, our present and previous 
investigations in combination with studies on the distribution of CRISPR/Cas patents by country, [37] 
technical category [37] and institutions [38] provide us a global picture of the impact of a plethora of 
organizational actors in the development and application of CRISPR/Cas technologies. In this picture, 
leading academic institutions supported by government agencies performed the most risky and 
innovative investigations for the development of CRISPR/Cas. In a second imitation stage of 
incremental innovation, networks of philanthropic, US military and international organizations 
support specific developments of CRISPR/Cas technologies in the Broad/Harvard/MIT system which 
could be related to the comparatively larger number of patents awarded to the Broad/Harvard/MIT 
system in comparison with the University of California. [38] A third stage of CRISPR/Cas research, the 
development of applications, is taking place disproportionately in Chinese academic institutions 
supported by Chinese governmental agencies [18, 38] and US for-profit companies. [37] Our results 
raise questions about the role of philanthropy in influencing predominantly publicly funded research 
trajectories, about democracy in publicly funded innovation, the role of the public in shouldering the 
risk and cost of long-term technology development, and the privatization of reward from that public 
investment. That is, society as a whole finances the radical innovation process through government 
agencies, assuming most of the risks of investing in new areas of knowledge and technology, while 
private actors participate in later stages, leading to the socialization of risk and the privatization of 
rewards. [17, 39]  
However, critical studies on the governance of the innovation process in biotechnology, particularly 
the governance of CRISPR/Cas technologies, have bypassed the important role of US charitable and 
philanthropic organizations as powerful actors that can redirect the trajectory of the development 
and application of genomic technologies in favour of specific interests or sectors of society. In that 
sense it is fundamental to further the study of the interaction between CRISPR/Cas research and 
philanthropy. A first strategy would be to measure the impact of philanthropic grants by analysing the 
expenditures of the sponsored projects. A consortium of 33 US public research universities is moving 
in that direction by connecting the information on their sponsors, the grants, project expenditures 
and final products like papers and patents. [40] Unfortunately, neither the University of California nor 
the Broad/Harvard/MIT system participate in this initiative. Another strategy would be to gather the 
views of researchers, administrators and philanthropic foundation on the impact of the grants in the 
development of CRISPR/Cas technologies. Any strategy to deepen knowledge about the role of 
philanthropic foundations in the development of genomic editing technologies necessarily requires a 
commitment to transparency on the part of the various participating actors. 
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 S1 figure. Correspondence analysis bi-plot of distinctive terms and papers reporting CRISPR/Cas 
investigation performed at the University of California System and the Broad/Harvard/MIT 
system. The round blue dots represent distinctive terms while the red squared dots are individual 
papers. The papers are named in the plot according to the type of research and institutional 
system as follow: “UC” stands for University of California System while “Br” stands for 
Broad/Harvard/MIT system; “BP” stand for biological phenomenon; RT stands for research tool; TI 
stands for developments or improvements of the technology; BA stands for biomedical 
applications; FEA stands for food and environmental systems applications, and IBA stands for 
industrial biotechnological applications. 
 
 
 S2 figure. Correspondence analysis bi-plot of distinctive terms and sets of papers grouped by the 
type of research and institution. The round blue dots represent distinctive terms while the red 
squared dots are the set of papers grouped by the type of research and institution as follow: UC” 
stands for University of California System while “Br” stands for Broad/Harvard/MIT system; “BP” 
stand for biological phenomenon; RT stands for research tool; TI stands for developments or 
improvements of the technology; BA stands for biomedical applications; FEA stands for food and 
environmental systems applications, and IBA stands for industrial biotechnological applications. 
 
